Seeking In Vivo and In Vitro Models Exhibiting Resistance to Immune Checkpoint Inhibitors

Daiichi Sankyo, a global pharmaceutical company, seeks research on in vivo animal models and in vitro cell/tumor tissue models that demonstrate resistance to immune checkpoint inhibitors (ICIs). The company aims to better understand resistance mechanisms in solid tumors to improve patient outcomes.

Approaches of interest

• Models with clearly defined tumor-intrinsic resistance mechanisms
• Research focusing on PD-1 and PD-L1 immune checkpoint pathways is highest interest
• Studies involving solid tumors (especially lung, breast, and pancreatic)
• Models reflecting clinical observations
• Research incorporating specific patient selection biomarkers

Out of scope:

• lood cancer models
• Models lacking clear resistance mechanisms
• Models with tumor-extrinsic resistance mechanisms
  
  Developmental stage of interest: All stages from basic research to registration are acceptable, provided there is a clear mechanism of resistance.

Email Cameron Sargent, CTTC Licensing Officer, at cameron.sargent@vanderbilt.edu for more information.

Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.